vorinostat has been researched along with Non-alcoholic Fatty Liver Disease in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.
Excerpt | Relevance | Reference |
---|---|---|
"Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide." | 1.51 | Gene expression profile-based drug screen identifies SAHA as a novel treatment for NAFLD. ( Chen, S; Cheng, J; Cheng, Z; Deng, L; Liang, B; Liu, Y; Tang, X; Wang, Z; Wen, Y; Xin, H, 2019) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cheng, Z | 1 |
Wen, Y | 1 |
Liang, B | 1 |
Chen, S | 1 |
Liu, Y | 1 |
Wang, Z | 1 |
Cheng, J | 1 |
Tang, X | 1 |
Xin, H | 1 |
Deng, L | 1 |
1 other study available for vorinostat and Non-alcoholic Fatty Liver Disease
Article | Year |
---|---|
Gene expression profile-based drug screen identifies SAHA as a novel treatment for NAFLD.
Topics: Diacylglycerol O-Acyltransferase; Drug Evaluation, Preclinical; Gene Expression Profiling; Hep G2 Ce | 2019 |